Volume 3.27 | Jul 22

Immunology of Infectious Disease News 3.27 July 22, 2015
Immunology of Infectious Disease News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Like Us on Facebook   IIDN on Twitter
Researchers Develop Aerosolized Vaccine that Protects Primates against Ebola
Researchers developed an inhalable vaccine that protects primates against Ebola. They characterized the immune response generated by vaccination against Ebola delivered to the respiratory tract as either an aerosol or liquid. [Press release from The University of Texas Medical Branch at Galveston discussing online prepublication in the Journal of Clinical Investigation] Press Release | Full Article
Learn more about how to activate and expand T cells with ImmunoCult™
PUBLICATIONS (Ranked by impact factor of the journal)
Long-Lived Plasma Cells Are Contained within the CD19CD38hiCD138+ Subset in Human Bone Marrow
Investigators used CD19, CD38, and CD138 to identify four plasma cell (PC) subsets in human bone marrow (BM). They found that the CD19CD38hiCD138+ subset was morphologically distinct, differentially expressed PC-associated genes, and exclusively contained PCs specific for viral antigens to which the subjects had not been exposed for more than 40 years. [Immunity]
| Graphical Abstract | Press Release

Inhibition of Ebola Virus Glycoprotein-Mediated Cytotoxicity by Targeting Its Transmembrane Domain and Cholesterol
Researchers report that the membrane-anchored glycoprotein (GP) is sufficient to induce the detachment of adherent cells. They showed that the detachment induced through either full-length GP1,2 or the subunit GP2 depends on cholesterol and the structure of the transmembrane domain. [Nat Commun]
| Press Release

Dengue Virus Infection Elicits Highly Polarized CX3CR1+ Cytotoxic CD4+ T Cells Associated with Protective Immunity
Researchers defined HLA-restricted CD4+ T-cell epitopes resulting from natural infection with dengue virus in a hyperepidemic setting. Ex vivo flow-cytometric analysis of DENV-specific CD4+ T cells revealed that the virus-specific cells were highly polarized, with a strong bias toward a CX3CR1+ Eomesodermin+ perforin+ granzyme B+ CD45RA+ CD4 CTL phenotype. [Proc Natl Acad Sci USA] Abstract

An Intranasal Virus-Like Particle Vaccine Broadly Protects Mice from Multiple Subtypes of Influenza A Virus
Scientists showed that mice were broadly protected against challenge with a wide variety of lethal influenza A virus infections with a virus-like particle vaccine cocktail. [mBio] Full Article | Press Release

Regulation of T Cell Function by MicroRNA-720
Invesitgators demonstrated that the percentage of hepatitis B virus (HBV)-specific CD8+ T cells is higher in the spleen of chronic HBV infection patients than that from peripheral blood and liver. miR-720 expression is upregulated in HBV-specific CD8+ T cells. [Sci Rep] Full Article


Antigen-Specific NK Cell Memory in Rhesus Macaques
Scientists found that splenic and hepatic natural killer (NK) cells from SHIVSF162P3-infected and SIVmac251-infected macaques specifically lysed Gag- and Env-pulsed dendritic cells in an NKG2-dependent fashion, in contrast to NK cells from uninfected macaques. [Nat Immunol] Abstract

Vpu Exploits the Cross-Talk between BST2 and the ILT7 Receptor to Suppress Anti-HIV-1 Responses by Plasmacytoid Dendritic Cells
Investigators showed that Vpu, the HIV-1 antagonist of BST2, suppresses TLR7-mediated type-I interferon production by plasmacytoid dendritic cells through a mechanism that relies on the interaction of BST2 on HIV-producing cells with ILT7. [PLoS Pathog] Full Article | Press Release

Potent Cell-Intrinsic Immune Responses in Dendritic Cells Facilitate HIV-1-Specific T Cell Immunity in HIV-1 Elite Controllers
Scientists showed that exposure of conventional dendritic cells from elite controllers to HIV-1 leads to a rapid and sustained production of type I interferons and upregulation of several interferon-stimulated effector genes. [PLoS Pathog] Full Article | Press Release

Bryostatin Activates HIV-1 Latent Expression in Human Astrocytes through a PKC and NF-ĸB-Dependent Mechanism
To broaden the inhibitory range and effectiveness of current antiretrovirals, the potential of bryostatin was investigated as a latent HIV-1 activator. Bryostatin reactivates latent viral infection in the NHA and U87 cells via activation of protein kinase C (PKC)-alpha and -delta, because the PKC inhibitors rottlerin and GF109203X abrogated the bryostatin effect. [Sci Rep] Full Article

Langerhans Cell–Dendritic Cell Cross-Talk via Langerin and Hyaluronic Acid Mediates Antigen Transfer and Cross-Presentation of HIV-1
Investigators demonstrated that langerin not only functions as a pattern recognition receptor but also as an adhesion receptor mediating clustering between Langerhans cells and dendritic cells. [J Immunol] Abstract

Restoration of CD4+ Responses to Copathogens in HIV-Infected Individuals on Antiretroviral Therapy Is Dependent on T Cell Memory Phenotype
To better understand the dynamics of Ag-specific CD4+ T cells during antiretroviral therapy (ART), scientists assessed the frequency, functional capacity, and memory profile of CD4+ T cells specific for Mycobacterium tuberculosis and CMV in 15 HIV-infected individuals before and 1 y after ART initiation [J Immunol] Abstract

Subscribe to our sister publications: Human Immunology News and Immune Regulation News!

Request your FREE copy of STEMCELL Technologies' new 2015 catalog!
HIV-1 Capsid: The Multifaceted Key Player in HIV-1 Infection
The authors review the curre understanding of the interactions between the viral capsid core and several cellular factors that enable efficient HIV-1 genome replication, timely core disassembly, nuclear import and the integration of the viral genome into the genome of the target cell. [Nat Rev Microbiol] Abstract

Visit our reviews page to see a complete list of reviews in the immunology of infectious disease research field.
Cholesterol Metabolism in Immune Cells Linked to HIV Progression
Lower levels of cholesterol in certain immune cells—a result of enhanced cholesterol metabolism within those cells—may help explain why some HIV-infected people are able to naturally control disease progression. [Press release from the National Institutes of Health discussing research presented at the 8th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention, Vancouver] Press Release

Starting Antiretroviral Treatment Early Improves Outcomes for HIV-Infected Individuals
A major international randomized clinical trial has found that HIV-infected individuals have a considerably lower risk of developing AIDS or other serious illnesses if they start taking antiretroviral drugs sooner, when their CD4+ T-cell count—a key measure of immune system health—is higher, instead of waiting until the CD4+ cell count drops to lower levels. [Press release from the National Institutes of Health discussing research presented at the 8th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention, Vancouver] Press Release

Argos Therapeutics to Present at 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention
Argos Therapeutics Inc. announced Irina Tcherepanova, Ph.D. will participate in a roundtable discussion on combination therapy trials at the “Towards an HIV Cure” symposium. [Press release from Argos Therapeutics Inc. discussing research to be presented at the 8th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention, Vancouver] Press Release

Novavax Announces Positive Top-Line Data from Phase I Ebola Vaccine Trial on WHO Teleconference
Novavax, Inc. announced positive top-line data from a Phase I clinical trial of its Ebola virus glycoprotein recombinant nanoparticle vaccine candidate adjuvanted with Matrix-M. [Press release from Novavax, Inc. discussing research presented at the World Health Organization’s (WHO) Fifth Teleconference on Ebola Vaccine Clinical Trials] Press Release

From our sponsor: Learn how HLA labs save resources with RoboSep™. Watch the webinar.
Bavarian Nordic Announces that the Oxford Vaccines Group has Initiated a Phase II Study of the Ebola Prime-Boost Vaccine Regimen Combining MVA-BN® Filo and Janssen’s AdVac® Technology
Bavarian Nordic A/S announced that the Oxford Vaccines Group has initiated a Phase II clinical study of the Ebola prime-boost vaccine regimen that combines Bavarian Nordic’s MVA-BN® Filo vaccine with the Ad26.ZEBOV vaccine from the Janssen Pharmaceutical Companies of Johnson & Johnson. [Bavarian Nordic A/S] Press Release

Bristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation for Investigational HIV-1 Attachment Inhibitor for Heavily Treatment-Experienced Patients
Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to the investigational compound BMS-663068 when used in combination with other antiretroviral agents for the treatment of HIV-1 infection in heavily treatment-experienced adult patients. [Bristol-Myers Squibb Company] Press Release

Tekmira Provides Update on TKM-Ebola-Guinea
Tekmira Pharmaceuticals Corporation announced that the Phase II clinical trial of TKM-Ebola-Guinea has reached a predefined statistical endpoint and enrollment has been closed. [Tekmira Pharmaceuticals Corporation ] Press Release

IAS Announces 2015 CIPHER Award Grantees, Commits to Largest-Ever Grant Program in 2016
As part of its continued commitment to support young and emerging investigators and address priority research gaps in paediatric HIV, the International AIDS Society (IAS) announced its 2015 award winners for the IAS Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Grant Program. [International AIDS Society] Press Release

Scripps Florida Scientists Receive $2.8 Million to Develop Innovative Approach to Latent HIV Infection
A team of scientists from the Scripps Research Institute in Jupiter received $2.8 million in grants to develop an HIV treatment. [Scripps Research Institute] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW BIT’s 6th Annual World Congress of Microbes
June 16, 2016
Gyeonggi, Korea

Visit our events page to see a complete list of events in the immunology of infectious disease community.
NEW Research Associate – Cell Biology (Editas Medicine)

NEW Senior Research Associate – CRISPR-Based Therapeutics (Editas Medicine)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Scientific Marketing Specialist – Immunology (STEMCELL Technologies Inc.)

Research Assistant – Immunotherapy for HIV Infection (California Institute of Technology)

Research Assistant – Molecular Immunology of HIV (University of Oxford)

Postdoctoral Position – Translational Immunology (University of Utah School of Medicine)

PhD Studentship – Veterinary and Animal Sciences (University of Milan)

Faculty Position – HIV Research (University of Pittsburgh)

Faculty Positions – Immunology/Infectious Disease (The Wistar Institute)

Postdoctoral Scientist – HIV Immunology (Gilead Sciences)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Immunology of Infectious Disease News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Immunology of Infectious Disease News: Archives | Events | Contact Us